Shareholders exercise their influence over Oasmia at the Annual General Meeting, the superior body of the company.
At the AGM, shareholders elect Board Members and also auditors when applicable. They also decide how to elect members of the nomination committee and vote on whether the CEO shall be discharged from liability for the fiscal year.
The AGM makes decisions concerning establishment of financial reports, allocation of earnings, fees for the Board of Directors and the auditors, guidelines for remuneration of the CEO and other Managers and other essential matters that require a decision by the Meeting. Normally, a simple majority decision is sufficient, but the Swedish Companies Act dictates other criteria in certain matters.
Shareholders who are registered pursuant to the company’s Articles of Association in Euroclear Sweden’s share register as of the record day may take part in the AGM, in person or by a representative. All shareholders have the same initiative, participation and voting rights.
Shareholders have the right to have any specific issue discussed at the AGM. Oasmia publishes a notice of the AGM six to four weeks before the Meeting. For the company to be able include the issue in the notice, a request must reach the company seven weeks before the AGM. Requests for an issue discussion are made to the Board of Directors and sent to the following address:
Oasmia Pharmaceutical AB
Att. The Board of Directors
SE 752 28 Uppsala